Skip to content

Perioperative outcomes of laparoscopic and robot-assisted major hepatectomies: A Single Institutional Randomized Controlled Trial

Perioperative outcomes of laparoscopic and robot-assisted major hepatectomies: A Single Institutional Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020870
Enrollment
Unknown
Registered
2019-01-21
Start date
2019-03-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Group 1:laparoscopic major hepatectomy
Group2: robotic major hepatectomy

Sponsors

The General Hospital of the People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) The preoperative diagnosis of primary hepatocellular carcinoma is clear and the pathological reports are consistent after operation; (2) the general condition and the function of important organs are good, and they can tolerate general anesthesia and hepatectomy; (3) the preoperative enhanced CT, contrast-enhanced ultrasound or MRI examination of the upper abdomen are performed, and the extent of resection is more than three segments (i.e. major hepatectomy); (4) Child-Pugh grade A or B of liver function, with no active liver Inflammation and severe portal hypertension; (5) Reserved liver volume/standard remnant liver volume (> 30%); (6) Complete clinical data; (7) The patient had agreed to sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) General anesthesia and hepatectomy can not be tolerated; (2) Child-Pugh grade C of liver function, with severe portal hypertension or active hepatitis; (3) severe epigastric adhesions caused by previous abdominal surgery, endoscopic surgical instruments can not be implanted or established; (4) With rupture of tumors and hemorrhagic peritoneal effusion were detected during operation; (5) treated by TACE, RF, radiotherapy and chemotherapy were performed before operation; (6) lack of clinical data.

Design outcomes

Primary

MeasureTime frame
Incidence of complications (Clavien-Dindo grade (> 3a);90-day mortality rate;

Secondary

MeasureTime frame
Operative time;Intraoperative blood loss;Intraoperative blood transfusion rate;Number of lymph nodes and positive lymph nodes (based on postoperative pathology);Negative rate of tumor margin;Time of first eating after operation;The length of hospital stay;

Countries

China

Contacts

Public ContactZhang Haifeng

The General Hospital of the People's Liberation Army

1228698339@qq.com+86 13520784615

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026